By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Protalix Biotherapeutics, Inc. 

2 Snunit Street, Science Park
P.O. Box 455
Karmiel    21000  Israel
Phone: 972-4-988-9488 Fax: 972-4-988-9489


SEARCH JOBS








Company News
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Interim Data From Phase 1/2 Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease 1/8/2015 7:28:28 AM
Protalix Biotherapeutics, Inc. (PLX) To Present At The 2015 J.P. Morgan Healthcare Conference 1/5/2015 1:35:21 PM
Protalix Biotherapeutics, Inc. (PLX) Announces New Strategy For Accelerated Growth 1/5/2015 7:12:32 AM
Protalix Biotherapeutics, Inc. (PLX) Appoints Moshe Manor As President And CEO 9/29/2014 8:22:43 AM
Protalix Biotherapeutics, Inc. (PLX) Announces Conference Call To Discuss ELELYSO Pediatric Approval And Provide Updates On Additional Programs 8/29/2014 8:40:08 AM
Protalix Biotherapeutics, Inc. (PLX) Names Shlomo Yanai As Chairman Of The Board Of Directors 7/24/2014 10:09:41 AM
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/27/2014 8:53:11 AM
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/23/2014 7:36:02 AM
Protalix Biotherapeutics, Inc. (PLX) Initiates Phase 2 Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease 6/18/2014 8:59:08 AM
Protalix Biotherapeutics, Inc. (PLX) CEO Will Retire This Year 6/13/2014 7:42:12 AM
12345678910...
//-->